Regulation and Role of EZH2 in Cancer

키워드

참고문헌 (174)

1. Morey L, "Polycomb group protein-mediated repression of transcription", Trends Biochem Sci, 35, pp.323~332 (2010)
2. Simon JA, "Mechanisms of polycomb gene silencing : knowns and unknowns", Nat Rev Mol Cell Biol, 10, pp.697~708 (2009)
3. O'Meara MM, "Inner workings and regulatory inputs that control Polycomb repressive complex 2", Chromosoma, 121, pp.221~234 (2012)
4. Koh CM, "Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms", Oncotarget, 2, pp.669~683 (2011)
5. Wang L, "c-Mycmediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma", Hepatology, 59, pp.1850~1863 (2014)
6. Sander S, "MYC stimulates EZH2 expression by repression of its negative regulator miR-26a", Blood, 112, pp.4202~4212 (2008)
7. Salvatori B, "Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2", Genes Cancer, 2, pp.585~592 (2011)
8. Suva ML, "EZH2 is essential for glioblastoma cancer stem cell maintenance", Cancer Res, 69, pp.9211~9218 (2009)
9. Bracken AP, "EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer", EMBO J, 22, pp.5323~5335 (2003)
10. Kalashnikova EV, "ANCCA", ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2, 2010, pp.70, 9402~9412
11. Duan Z, "Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA", ATAD2 in the prostate via MLL histone methylase complex, 2013, pp.73, 455~466
12. Richter GH, "EZH2 is a mediator of EWS", FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation, 2009, pp.106, 5324~5329
13. Tiwari N, "Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming", Cancer Cell, 23, pp.768~783 (2013)
14. Garipov A, "NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells", Mol Cancer Res, 11, pp.360~369 (2013)
15. Lin YW, "Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer", J Pathol, 230, pp.277~290 (2013)
16. Kunderfranco P, "ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer", PLoS One, 5, pp.e10547~ (2010)
17. Chang CJ, "EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling", Cancer Cell, 19, pp.86~100 (2011)
18. Fujii S, "MEKERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes", Oncogene, 30, pp.4118~4128 (2011)
19. Esposito F, "Down-regulation of the miR-25 and miR- 30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2", J Clin Endocrinol Metab, 97, pp.E710~E718 (2012)
20. Zhang B, "Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer", Carcinogenesis, 32, pp.2~9 (2011)
21. Lu J, "MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2", Cancer Res, 71, pp.225~233 (2011)
22. Varambally S, "Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer", Science, 322, pp.1695~1699 (2008)
23. Friedman JM, "The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2", Cancer Res, 69, pp.2623~2629 (2009)
24. Wang HJ, "MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion", Eur J Cancer, 46, pp.2295~2303 (2010)
25. Banerjee R, "The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma", Oncogene, 30, pp.4339~4349 (2011)
26. Smits M, "miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis", Oncotarget, 1, pp.710~720 (2010)
27. Zhang JG, "MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2", J Thorac Oncol, 6, pp.671~678 (2011)
28. Liu X, "MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines", Biochem J, 440, pp.23~31 (2011)
29. Qiu S, "Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4", 6-pRb-E2F1 signal loop in glioblastoma multiforme, 2013, pp.1832, 1697~1707
30. Zhang H, "MiR-138 inhibits tumor growth through repression of EZH2 in nonsmall cell lung cancer", Cell Physiol Biochem, 31, pp.56~65 (2013)
31. Kong D, "Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM", PLoS One, 7, pp.e33729~ (2012)
32. Cai K, "Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells", Oncol Rep, 28, pp.2101~2106 (2012)
33. Zheng F, "The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2", Gut, 61, pp.278~289 (2012)
34. Xie L, "microRNA- 124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer", Mol Cell Biochem (2014)[DOI]
35. Huang SD, "MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma", Mol Cancer, 11, pp.51~ (2012)
36. Alajez NM, "Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98", Cell Death Dis, 1, pp.e85~ (2010)
37. Luo C, "miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes", J Invest Dermatol, 133, pp.768~775 (2013)
38. Guo Y, "miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling", FEBS J, 280, pp.4531~4538 (2013)
39. Xia H, "MiR-214 targets beta-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma", PLoS One, 7, pp.e44206~ (2012)
40. Shen J, "EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2", Nature, 497, pp.383~387 (2013)
41. Caretti G, "The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation", Genes Dev, 18, pp.2627~2638 (2004)
42. Yang Y, "A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma", Oncogene, 32, pp.3432~3442 (2013)
43. Tong ZT, "EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1", HDAC2 and Snail to inhibit E-cadherin, 2012, pp.31, 583~594
44. Corvetta D, "Physical interaction between MYCN oncogene and polycomb repressive complex 2(PRC2)in neuroblastoma : functional and therapeutic implications", J Biol Chem, 288, pp.8332~8341 (2013)
45. Mukhopadhyay NK, "Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2", Oncogene, 33, pp.3235~3245 (2014)
46. Boulay G, "Hypermethylated in cancer 1(HIC1)recruits polycomb repressive complex 2(PRC2)to a subset of its target genes through interaction with human polycomb-like(hPCL)proteins", J Biol Chem, 287, pp.10509~10524 (2012)
47. Hwang-Verslues WW, "Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy", Proc Natl Acad Sci U S A, 110, pp.12331~12336 (2013)
48. Zhang H, "Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II", J Cell Biol, 193, pp.475~487 (2011)
49. Leseva M, "E2f6-mediated repression of the meiotic Stag3 and Smc1beta genes during early embryonic development requires Ezh2 and not the de novo methyltransferase Dnmt3b", Epigenetics, 8, pp.873~884 (2013)
50. Cakouros D, "Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A", Arf locus in mesenchymal stem cells, 2012, pp.32, 1433~1441
51. Ciavatta DJ, "Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis", J Clin Invest, 120, pp.3209~3219 (2010)
52. Gupta RA, "Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis", Nature, 464, pp.1071~1076 (2010)
53. Kogo R, "Long noncoding RNA HOTAIR regulates polycombdependent chromatin modification and is associated with poor prognosis in colorectal cancers", Cancer Res, 71, pp.6320~6326 (2011)
54. Kim K, "HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer", Oncogene, 32, pp.1616~1625 (2013)
55. Liu Z, "The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1", CIP1) expression, 2013, pp.8, e77293~
56. Tsai MC, "Long noncoding RNA as modular scaffold of histone modification complexes", Science, 329, pp.689~693 (2010)
57. Yang F, "Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans", Hepatology, 54, pp.1679~1689 (2011)
58. Prensner JR, "Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression", Nat Biotechnol, 29, pp.742~749 (2011)
59. Luo M, "Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression", Cancer Lett, 333, pp.213~221 (2013)
60. He W, "linc-UBC1 physically associates with polycomb repressive complex 2(PRC2)and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer", Biochim Biophys Acta, 1832, pp.1528~1537 (2013)
61. Zhao J, "Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome", Science, 322, pp.750~756 (2008)
62. Rapicavoli NA, "The long noncoding RNA Six3OS acts in trans to regulate retinal development by modulating Six3 activity", Neural Dev, 6, pp.32~ (2011)
63. Li Q, "AS1DHRS4, a head-to-head natural antisense transcript, silences the DHRS4 gene cluster in cis and trans", Proc Natl Acad Sci U S A, 109, pp.14110~14115 (2012)
64. Zhu L, "Downregulated LncRNA-ANCR promotes osteoblast differentiation by targeting EZH2 and regulating Runx2 expression", Biochem Biophys Res Commun, 432, pp.612~617 (2013)
65. Kaneko S, "Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin", Mol Cell, 53, pp.290~300 (2014)
66. Kim DH, "MicroRNA-directed transcriptional gene silencing in mammalian cells", Proc Natl Acad Sci U S A, 105, pp.16230~16235 (2008)
67. Guil S, "Intronic RNAs mediate EZH2 regulation of epigenetic targets", Nat Struct Mol Biol, 19, pp.664~670 (2012)
68. Wang L, "BRCA1 is a negative modulator of the PRC2 complex", EMBO J, 32, pp.1584~1597 (2013)
69. Kaneko S, "Phosphorylation of the PRC2 component Ezh2 is cell cycleregulated and up-regulates its binding to ncRNA", Genes Dev, 24, pp.2615~2620 (2010)
70. da Rocha ST, "Jarid2 is implicated in the initial Xist-induced targeting of PRC2 to the inactive X chromosome", Mol Cell, 53, pp.301~316 (2014)
71. Cha TL, "Aktmediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3", Science, 310, pp.306~310 (2005)
72. Xu K, "EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent", Science, 338, pp.1465~1469 (2012)
73. Kim E, "Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells", Cancer Cell, 23, pp.839~852 (2013)
74. Sahasrabuddhe AA, "Oncogenic Y641 mutations in EZH2 prevent Jak2", beta-TrCP-mediated degradation, 2014, ~
75. Chen S, "Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2", Nat Cell Biol, 12, pp.1108~1114 (2010)
76. Wu SC, "Cyclin-dependent kinase 1(CDK1)-mediated phosphorylation of enhancer of zeste 2(Ezh2)regulates its stability", J Biol Chem, 286, pp.28511~28519 (2011)
77. Wei Y, "CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells", Nat Cell Biol, 13, pp.87~94 (2011)
78. Minnebo N, "NIPP1 maintains EZH2 phosphorylation and promoter occupancy at proliferation-related target genes", Nucleic Acids Res, 41, pp.842~854 (2013)
79. Li J, "EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia", Nat Neurosci, 16, pp.1745~1753 (2013)
80. Palacios D, "TNF", p38alpha, Cell Stem Cell, pp.2010, 7[DOI]
81. Chu CS, "O-GlcNAcylation regulates EZH2 protein stability and function", Proc Natl Acad Sci U S A, 111, pp.1355~1360 (2014)
82. Riising EM, "The polycomb repressive complex 2 is a potential target of SUMO modifications", PLoS One, 3, pp.e2704~ (2008)
83. Yu YL, "Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke", EMBO Mol Med, 5, pp.531~547 (2013)
84. Zoabi M, "PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins", Biochem Biophys Res Commun, 408, pp.393~398 (2011)
85. Lee J, "Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells", Cancer Cell, 13, pp.69~80 (2008)
86. Morin RD, "Somatic mutations altering EZH2(Tyr641)in follicular and diffuse large B-cell lymphomas of germinal-center origin", Nat Genet, 42, pp.181~185 (2010)
87. Sneeringer CJ, "Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3(H3K27)in human B-cell lymphomas", Proc Natl Acad Sci U S A, 107, pp.20980~20985 (2010)
88. Beguelin W, "EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation", Cancer Cell, 23, pp.677~692 (2013)
89. Majer CR, "A687V EZH2 is a gain-of-function mutation found in lymphoma patients", FEBS Lett, 586, pp.3448~3451 (2012)
90. McCabe MT, "Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27(H3K27)", Proc Natl Acad Sci U S A, 109, pp.2989~2994 (2012)
91. Lewis PW, "Inhibition of PRC2 activity by a gain-offunction H3 mutation found in pediatric glioblastoma", Science, 340, pp.857~861 (2013)
92. Bender S, "Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas", Cancer Cell, 24, pp.660~672 (2013)
93. Chan KM, "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression", Genes Dev, 27, pp.985~990 (2013)
94. Bachmann IM, "EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast", J Clin Oncol, 24, pp.268~273 (2006)
95. Raman JD, "Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder", Clin Cancer Res, 11(24 Pt 1), pp.8570~8576 (2005)
96. Matsukawa Y, "Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer", Cancer Sci, 97, pp.484~491 (2006)
97. Kondo Y, "Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas", Hepatol Res, 37, pp.974~983 (2007)
98. Ougolkov AV, "Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2", Clin Cancer Res, 14, pp.6790~6796 (2008)
99. Lee HW, "Expression of EZH2 in renal cell carcinoma as a novel prognostic marker", Pathol Int, 62, pp.735~741 (2012)
100. Rao ZY, "EZH2 supports ovarian carcinoma cell invasion and", or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients, 2010, pp.31, 1576~1583
101. Crea F, "Clinical significance of Polycomb gene expression in brain tumors", Mol Cancer, 9, pp.265~ (2010)
102. Yamada A, "Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus", Int J Oncol, 38, pp.345~353 (2011)
103. Behrens C, "EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma", Clin Cancer Res, 19, pp.6556~6565 (2013)
104. Alford SH, "Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression", Breast Cancer Res Treat, 132, pp.429~437 (2012)
105. Crea F, "Pharmacologic disruption of Polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer", Mol Cancer, 10, pp.40~ (2011)
106. Gonzalez ME, "EZH2 expands breast stem cells through activation of NOTCH1 signaling", Proc Natl Acad Sci U S A, 111, pp.3098~3103 (2014)
107. Li X, "Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia", Am J Pathol, 175, pp.1246~1254 (2009)
108. Nikoloski G, "Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes", Nat Genet, 42, pp.665~667 (2010)
109. Ernst T, "Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders", Nat Genet, 42, pp.722~726 (2010)
110. Muto T, "Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders", J Exp Med, 210, pp.2627~2639 (2013)
111. Ntziachristos P, "Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia", Nat Med, 18, pp.298~301 (2012)
112. Simon C, "A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia", Genes Dev, 26, pp.651~656 (2012)
113. Mallen-St Clair J, "EZH2 couples pancreatic regeneration to neoplastic progression", Genes Dev, 26, pp.439~444 (2012)
114. Bracken AP, "The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells", Genes Dev, 21, pp.525~530 (2007)
115. Ezhkova E, "Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells", Cell, 136, pp.1122~1135 (2009)
116. Reynolds PA, "Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells", J Biol Chem, 281, pp.24790~24802 (2006)
117. Sasaki M, "Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis", J Pathol, 215, pp.175~183 (2008)
118. Wang C, "Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma", Mol Carcinog, 52, pp.229~236 (2013)
119. Yu H, "PRC2", EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ, 2012, pp.7, e51239~
120. Fujii S, "Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells", Cancer Sci, 99, pp.738~746 (2008)
121. Cao Q, "Repression of E-cadherin by the polycomb group protein EZH2 in cancer", Oncogene, 27, pp.7274~7284 (2008)
122. Chen Y, "Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin", Hepatology, 46, pp.200~208 (2007)
123. Cheng AS, "EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis", Cancer Res, 71, pp.4028~4039 (2011)
124. Yang X, "CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells", PLoS One, 4, pp.e5011~ (2009)
125. Guo J, "EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo", Cancer Sci, 102, pp.530~539 (2011)
126. Yu J, "The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer", Oncogene, 29, pp.5370~5380 (2010)
127. Wu L, "CCN3", NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor, 2014, pp.33, 504~513
128. Shin YJ, "The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells", PLoS One, 7, pp.e30393~ (2012)
129. Min J, "An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB", Nat Med, 16, pp.286~294 (2010)
130. Du J, "FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells", Breast Cancer Res Treat, 131, pp.65~73 (2012)
131. Pathiraja TN, "Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer", Sci Transl Med, 6, pp.229~241 (2014)
132. Zeidler M, "The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells", Neoplasia, 7, pp.1011~1019 (2005)
133. Lu H, "Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4", Cell Death Dis, 4, pp.e776~ (2013)
134. Marchesi I, "The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation", Cell Cycle, 11, pp.3828~3836 (2012)
135. Wang C, "EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR", Cancer Res, 72, pp.315~324 (2012)
136. Fujii S, "Enhancer of zeste homologue 2(EZH2)down-regulates RUNX3 by increasing histone H3 methylation", J Biol Chem, 283, pp.17324~17332 (2008)
137. Taniguchi H, "Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer", Oncogene, 31, pp.1988~1994 (2012)
138. Wu ZL, "Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression", Cell Death Differ, 17, pp.801~810 (2010)
139. Tan J, "Phar-macologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells", Genes Dev, 21, pp.1050~1063 (2007)
140. De Carvalho DD, "BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients", Oncogene, 30, pp.223~233 (2011)
141. Lu C, "Regulation of tumor angiogenesis by EZH2", Cancer Cell, 18, pp.185~197 (2010)
142. Asangani IA, "Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer", Mol Cell, 49, pp.80~93 (2013)
143. Cao Q, "Coordinated regulation of Polycomb group complexes through microRNAs in cancer", Cancer Cell, 20, pp.187~199 (2011)
144. Shi B, "Integration of estrogen and Wnt signaling circuits by the Polycomb group protein EZH2 in breast cancer cells", Mol Cell Biol, 27, pp.5105~5119 (2007)
145. Jung HY, "PAF and EZH2 induce Wnt", beta-catenin signaling hyperactivation, 2013, pp.52, 193~205
146. Lee ST, "Context- specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers", Mol Cell, 43, pp.798~810 (2011)
147. Yan J, "EZH2 overexpression in natural killer", T-cell lymphoma confers growth advantage independently of histone methyltransferase activity, 2013, pp.121, 4512~4520
148. Lee JM, "EZH2 generates a methyl degron that is recognized by the DCAF1", DDB1, Mol Cell, pp.2012, 48[DOI]
149. He A, "PRC2 directly methylates GATA4 and represses its transcriptional activity", Genes Dev, 26, pp.37~42 (2012)
150. Su IH, "Polycomb group protein ezh2 controls actin polymerization and cell signaling", Cell, 121, pp.425~436 (2005)
151. Bryant RJ, "The Polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells", Prostate, 68, pp.255~263 (2008)
152. Campbell S, "Polycomb repressive complex 2 contributes to DNA doublestrand break repair", Cell Cycle, 12, pp.2675~2683 (2013)
153. Gonzalez ME, "Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1", Oncogene, 28, pp.843~853 (2009)
154. Gonzalez ME, "Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer", Cancer Res, 71, pp.2360~2370 (2011)
155. Puppe J, "BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb repressive complex 2-inhibitor 3-deazaneplanocin A", Breast Cancer Res, 11, pp.R63~ (2009)
156. Alimova I, "Targeting the enhancer of zeste homologue 2 in medulloblastoma", Int J Cancer, 131, pp.1800~1809 (2012)
157. Kemp CD, "Polycomb repressor complex-2 is a novel target for mesothelioma therapy", Clin Cancer Res, 18, pp.77~90 (2012)
158. Kalushkova A, "Polycomb target genes are silenced in multiple myeloma", PLoS One, 5, pp.e11483~ (2010)
159. Gannon OM, "Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation", Clin Cancer Res, 19, pp.428~441 (2013)
160. Fujiwara T, "3-Deazaneplanocin A(DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation", J Biol Chem, 289, pp.8121~8134 (2014)
161. McCabe MT, "EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations", Nature, 492, pp.108~112 (2012)
162. Knutson SK, "A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells", Nat Chem Biol, 8, pp.890~896 (2012)
163. Knutson SK, "Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma", Mol Cancer Ther, 13, pp.842~854 (2014)
164. Qi W, "Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation", Proc Natl Acad Sci U S A, 109, pp.21360~21365 (2012)
165. Hua WF, "Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells", Eur J Pharmacol, 637, pp.16~21 (2010)
166. Bao B, "Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression", Cancer Res, 72, pp.335~345 (2012)
167. Dimri M, "Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells", Carcinogenesis, 31, pp.489~495 (2010)
168. Wang S, "Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2", Cancer Sci, 104, pp.750~759 (2013)
169. Avan A, "Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells", Mol Cancer Ther, 11, pp.1735~1746 (2012)
170. Fiskus W, "Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells", Clin Cancer Res, 18, pp.6227~6238 (2012)
171. Hayden A, "S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition", Breast Cancer Res Treat, 127, pp.109~119 (2011)
172. Sun F, "Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells", Mol Cancer Ther, 8, pp.3191~3202 (2009)
173. Lv Y, "The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma", Oncol Rep, 28, pp.147~154 (2012)
174. Hu S, "Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo", Cancer Biol Ther, 10, pp.788~795 (2010)

관련 논문AI추천